Management of Stage III Non–Small-Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update
Authors:
- Nofisat IsmailaNINofisat Ismaila
- for the Management of Stage III NSCLC Guideline Expert PanelFPfor the Management of Stage III NSCLC Guideline Expert Panel
- Mara B. AntonoffMAMara B. Antonoff
- Douglas A. ArenbergDADouglas A. Arenberg
- Jeffrey BradleyJBJeffrey Bradley
- Elizabeth DavidEDElizabeth David
- Frank DetterbeckFDFrank Detterbeck
- Martin FrühMFMartin Früh
- Matthew A. GubensMGMatthew A. Gubens
- Amy C. MooreAMAmy C. Moore
- 20 September 2023
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 41 (27) , 4430-4432
Abstract
ASCO Rapid Recommendations Updates highlight revisions to select ASCO guideline recommendations as a response to the emergence of new and practice-changing data. The rapid updates are supported by an evidence review and follow the guideline development processes outlined in the ASCO Guideline Methodology Manual. The goal of these articles is to disseminate updated recommendations, in a timely manner, to better inform health practitioners and the public on the best available cancer care options. See the Appendix for disclaimers and other important information ( Appendix 1 and Appendix 2 , online only).Keywords
This publication has 6 references indexed in Scilit:
- Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung CancerNew England Journal of Medicine, 2023
- Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non–Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA TrialJournal of Clinical Oncology, 2023
- Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung CancerNew England Journal of Medicine, 2022
- Management of Stage III Non–Small-Cell Lung Cancer: ASCO GuidelineJournal of Clinical Oncology, 2022
- Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I-IIIA Completely Resected Non–Small-Cell Lung Cancer: ASCO Guideline Rapid Recommendation UpdateJournal of Clinical Oncology, 2022
- Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trialThe Lancet, 2021